CRBP Stock Analysis: Buy, Sell, or Hold?
CRBP - Corbus Pharmaceuticals Holdings, Inc.
$10.17
0.19 (1.90%)
▲
5d:
+10.06%
30d:
+20.78%
90d:
+24.94%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 05, 2026
28d
Smart Money Accumulation
CRBP is down 8.2% this week, but smart money is accumulating calls. Top strike: $12.5 2026-06-18 with 1,803 OI. Call ratio: 100% View Scanner →
Strength: 9.1/10
Get Alerted When CRBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRBP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CRBP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRBP is currently trading at $10.17, which is considered extended relative to its 30-day fair value range of $8.28 to $9.69.
Technical Outlook: Technically, CRBP is in a downtrend. Immediate support is located at $8.10, while resistance sits at $10.50.
Market Sentiment: CRBP has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (6th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $42.11 (+314.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRBP is in a downtrend. Immediate support is located at $8.10, while resistance sits at $10.50.
Market Sentiment: CRBP has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (6th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $42.11 (+314.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$8.28 -
$9.69
Company Quality Score
64/100
(BUY)
Options IV Signal
6th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 6th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 314.1% below Wall St target ($42.11)
Fair Price Analysis
30-Day Fair Range
$8.28 -
$9.69
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$1.42
(13.9%)
Support & Resistance Levels
Support Level
$8.10
Resistance Level
$10.50
Current Trend
Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.06
Wall Street Target
$42.11
(+314.1%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: April 06, 2026 12:13 AM ET
Data refreshes hourly during market hours. Next update: 1:13 AM
Data refreshes hourly during market hours. Next update: 1:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Dominic Smethurst
SELL
3285 shares
2026-02-03
Ian Hodgson
SELL
2415 shares
2026-02-03
Cormorant Asset Manageme…
SELL
30029 shares
2025-12-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$43 | 65 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
